(Q38236876)

31 August 2017

title

Treatment of intermediate-stage hepatocellular carcinoma (English)

1 reference

31 August 2017

1

1 reference

31 August 2017

3

1 reference

31 August 2017

4

Jean-Luc Raoul

1 reference

31 August 2017

2

Marine Gilabert

1 reference

31 August 2017

language of work or name

English

0 references

publication date

5 August 2014

1 reference

Nature Reviews Clinical Oncology

31 August 2017

published in

1 reference

31 August 2017

volume

11

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

525-535

1 reference

31 August 2017

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Performance status assessment in cancer patients. An inter-observer variability study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Loco-regional treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Pilot Study of Transcatheter Arterial Chemoembolization with Degradable Starch Microspheres in Patients With Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Chemoembolization for intermediate HCC: is there proof of survival benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Diagnosis and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radioembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Liver disease induced by radioembolization of liver tumors: description and possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Hepatocellular Carcinoma (HCC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Rising incidence of hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Simplified staging for hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Drug-eluting Beads for Liver Embolization: Concentration of Doxorubicin in Tissue and in Beads in a Pig Model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.122

Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25091611

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2014.122

1 reference

31 August 2017

1 reference